Skip to main content

Coda Genomics Closes $1.6M in Series B Funding

NEW YORK, Feb. 28 (GenomeWeb News) - Coda Genomics said today that it has secured $1.6 million in a Series B funding round.


The round was led by the Life Science Angels and includes venture capital firm Monitor Ventures and previous investors from the Tech Coast Angels. The round has two representatives on the Coda board of directors: Ken Kelley from the Life Science Angels, and Neal Bhadkamkar from Monitor Ventures.


Coda offers gene kits and services optimized to assemble DNA into single genes that the company said "are guaranteed to express specific proteins." The genes are optimized for correct self assembly, and also for characteristics that guarantee they express the desired protein at high levels in a biological expression system of choice, Coda said.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.